Syntex LLC

Syntex (u.s.a.) Inc.

Eugene J Segre

This invention relates to a method of treating allergic, dermatologic and rheumatic diseases in mammals which comprises daily orally administering to said mammal in a single dose an effective amount of 6-chloro-11.beta.,17.alpha.,21-trihydroxypregna-1,4,6-triene-3,20-dione.

Method of treating diseases by daily administration of

This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle. In a particular regimen, a combination of estrogen and progestogen is administered starting with the 5th day of the cycle and continuing every other day through the 25th day of the cycle, and starting with the 6th day of the cycle and continuing every other day through the 24th day of the cycle only progestogen is administered. The remaining seven days are dosage-free or the regimen is completed by use of placebos or other nonhormonal supplements. Dispensing packages for holding unit dosage forms for oral ingestion of one unit dosage form daily in the appropriate sequence during a single cycle of medication administration are also described.

Growing community of inventors

Los Altos, CA, United States of America

Eugene J Segre